Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 27;8(26):41866-41875.
doi: 10.18632/oncotarget.16383.

Human microRNA expression in sporadic and FAP-associated desmoid tumors and correlation with beta-catenin mutations

Affiliations

Human microRNA expression in sporadic and FAP-associated desmoid tumors and correlation with beta-catenin mutations

Aldo Cavallini et al. Oncotarget. .

Abstract

Desmoid tumors (DT) are rare, benign, fibroblastic neoplasm with challenging histological diagnosis. DTs can occur sporadically or associated with the familial adenomatous polyposis coli (FAP). Most sporadic DTs are associated with β-catenin gene (CTNNB1) mutations, while mutated APC gene causes FAP disease. microRNAs (miRNAs) are involved in many human carcinogenesis.The miRNA profile was analyzed by microarray in formalin-fixed, paraffin-embedded (FFPE) specimens of 12 patients (8 sporadic, 4 FAP-associated) and 4 healthy controls. One hundred and one mRNAs resulted dysregulated, of which 98 in sporadic DTs and 8 in FAP-associated DTs, 5 were shared by both tumors. Twenty-six miRNAs were then validated by RT-qPCR in 23 sporadic and 7 FAP-associated DT samples matched with healthy controls. The qPCR method was also used to evaluate the CTNNB1 mutational status in sporadic DTs. The correlation between sporadic DTs and miRNA expression showed that miR-21-3p increased in mutated versus wild-type DTs, while miR-197-3p was decreased. The mRNA expression of Tetraspanin3 and Serpin family A member 3, as miR-21-3p targets, and L1 Cell Adhesion Molecule, as miR-197-3p target, was also evaluate. CTNNB1 mutations associated to miRNA dysregulation could affect the genesis and the progression of this disease and help histological diagnosis of sporadic DTs.

Keywords: CTNNB1 mutations; desmoid tumor; microRNA; serpin family A member 3 (SERPINA3) mRNA; tetraspanin3 (TSPAN3) mRNA.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

All authors declare that there are no conflicts of interest.

Figures

Figure 1
Figure 1. Validation of microarray analysis
Comparison between microarray (mean) and RT-qPCR (mean ± SD) data (A) Comparison of the miRNA profiling in sporadic desmoid tumors. (B) Comparison of the miRNA profiling in FAP-associated desmoid tumors. The Y axis shows the fold change values between tumor samples and controls obtained by microarray and RT-qPCR experiments, respectively.
Figure 2
Figure 2. miR-21-3p and mR-197-3p expression in sporadic desmoids with and without CNTTB1 gene mutations
Of 26 patients with sporadic desmoids, 14 showed the gene mutated (M), while the remaining 12 had the wild type gene (Wt). The scatter dot blot graph shows the distribution of each miRNA relative to CNTTB1 mutational status. The miRNA levels, generated by qRT-PCR, are expressed as log2 (2−ΔΔCt) that represents the fold change values of tumor vs. control samples. Differences between two M and Wt groups were evaluated by nonparametric Mann-Whitney test with significant value of p < 0.05.
Figure 3
Figure 3. Expression of the miR-21-3p and miR-197-3p mRNA targets
miR-21-3p promotes the L1CAM expression, while the negative regulation for COL1A1 and MAT2A is not observed in mutated (M) vs. wild type (Wt) sporadic desmoid tumors. Decreased levels of miR-197-3p induce a TSPAN3 and SEPINA3 mRNA over-expression in M vs. Wt sporadic tumors. The gene expression was quantified using RT-qPCR. Bars represent the mean ± SD and the values are significant for p < 0.05.

Similar articles

Cited by

References

    1. Fletcher JA, Bridge JA, Hogendoorn PCW. WHO Classification of Tumors of Soft Tissue and Bone. Lyon: IARC Press; 2013. Desmoid-type fibromatoses; pp. 72–73.
    1. Schlemmer M. Desmoid tumors and deep fibromatoses. Hematol Oncol Clin North Am. 2005;19:565–571. - PubMed
    1. Clark SK, Phillips RKS. Desmoids in familial adenomatous polyposis. Brit J Surg. 1996;83:1494–1504. - PubMed
    1. Kasper B, Strobel P, Hohenberger P. Desmoid tumors: clinical features and treatment options for advanced disease. Oncologist. 2011;16:682–693. doi: 10.1634/theoncologist.2010-0281. - DOI - PMC - PubMed
    1. Kasper B, Baumgarten C, Bonvalot S, Haas R, Haller F, Hohenberger P, Moreau G, van der Graaf WT, Gronchi A, Desmoid Working Group Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients’ and professionals’ expertise - a sarcoma patients EuroNet and European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer. 2015;51:127–136. doi: 10.1016/j.ejca.2014.11.005. - DOI - PubMed

MeSH terms

Supplementary concepts